PubMed Health⌕ Search

Biomedical subjects

T Spector

Publications and source records attributed to T Spector.

At least 91 records · Page 5Linked to original sources
PubMed1984

Folic acid does not inactivate xanthine oxidase.

In response to a recent report (Lewis, A.S., Murphy, L., Mcalla, C., Fleary, M., and Purcell, S. (1984) J. Biol. Chem. 259, 12-15) that folic acid was a potent inactivator of xanthine oxidase, the details of this apparent inactivation were studied. In confirmation, we also found that commercially available folic acid produced a time-dependent progressive inhibition (apparent inactivation) of xanthine oxidase. A plot of the pseudo-first order rate constant of the decay of enzyme activity versus the concentration of folic acid resulted in a straight line. This indicated that the progressive inhibition was caused by a slow second order combination of an inhibitor with the enzyme. The second order rate constant for this association (slope of replot) was 5.7 X 10(3) M-1 S-1. The slowness of this constant together with the observation that complete inactivation did not occur suggested that the progressive inhibition might be due to the slow binding of a high affinity contaminant. This was corroborated by the finding that the association constant was decreased to 1.6 X 10(2) M-1 S-1 after partially purifying the folic acid. The compound most likely to be producing this inhibition is pterin aldehyde (2-NH2-4-OH-pteridine-6-aldehyde), a photolytic breakdown product of folic acid. Pterin aldehyde was found to be a progressive inhibitor of xanthine oxidase with an association constant of 2.2 X 10(5) M-1 S-1. When the apparent association constants of commercial and purified folic acid were adjusted to reflect the pterin aldehyde content (3.6% and 0.2%, respectively), they became similar to the association constant of pterin aldehyde. Thus, it seems that the apparent inactivation of xanthine oxidase by folic acid was caused by the slow binding of contaminating pterin aldehyde.

Animals↗
PubMed1984

Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase.

The triphosphate form of 9-[(2-hydroxyethoxy)-methyl]guanine (acyclovir), ACVTP, inactivates the herpes simplex virus type 1 DNA polymerase. ACVTP does not innately inactivate resting polymerase, but becomes an inactivator only while being processed as an alternative substrate. Pseudo first-order rates of inactivation were measured at varying concentrations of ACVTP and fixed concentrations of the natural substrate, deoxyguanosine triphosphate. These studies indicated that a reversible enzyme-ACVTP (Michaelis-type) complex is formed at the active site prior to inactivation. The formation of this complex was competitively retarded by deoxyguanosine triphosphate. An apparent dissociation constant (KD) of 3.6 +/- 0.2 (S.D.) nM was determined for ACVTP from this reversible complex. A second method for the estimation of the KD which used the extrapolated initial velocities produced a value of 5.9 +/- 0.4 (S.D.) nM. The rate of conversion of the reversible complex to the inactivated complex, at saturating ACVTP, was calculated to be 0.24 min-1. No reactivation of enzyme activity was detected following isolation of the inactivated complex by rapid desalting on Sephadex G-25. Under these conditions, an overall reactivation rate of 1.5 X 10(-5) min-1 could have been easily detected. Therefore, the overall inhibition constant must have been less than 3 pM. In contrast, when host DNA polymerase alpha was incubated with 14 microM ACVTP, only 60% inhibition of enzyme activity was observed, but inactivation was not detected. These data indicate that ACVTP functions as a suicide inactivator of the herpes simplex virus type 1 DNA polymerase, and is only a weak reversible inhibitor of DNA polymerase alpha.

Acyclovir↗
PubMed1984

Monophosphates of formycin B and allopurinol riboside. Interactions with leishmanial and mammalian succino-AMP synthetase and GMP reductase.

Formycin B 5'-monophosphate (Form B-MP) and allopurinol riboside 5'-monophosphate ( HPPR -MP) are isomers of IMP that are metabolically produced when Leishmania spp. are incubated with the antileishmanial agents formycin B and allopurinol or allopurinol riboside. The interactions of Form B-MP with succino -AMP synthetase and GMP reductase from both leishmanial and mammalian sources were compared with the data of earlier studies with HPPR -MP. Both analogs could substitute for IMP as a substrate for succino -AMP synthetase isolated from Leishmania donovani. The V'max values of Form B-MP and HPPR -MP were about 1% of the V'max of IMP. Only Form B-MP (and not HPPR -MP) could serve as an alternative substrate for mammalian succino -AMP synthetase. The V'max of Form B-MP was 40% that of IMP. The corresponding analogs of AMP, ADP and ATP were produced when Formycin B was incubated with mouse L cells. The Formycin A residue was incorporated into the cellular RNA. The amount of Formycin A-TP produced (relative to ATP) in mouse L cells was considerably less than that produced in Leishmania spp. Both Form B-MP and HPPR -MP were inhibitors of partially purified GMP reductase from L. donovani. The binding of Form B-MP and HPPR -MP to human GMP reductase was 40- and 100-fold weaker, respectively, than the binding to leishmanial GMP reductase. Pretreatment of promastigotes of L. donovani with either allopurinol or Formycin B resulted in greater than 95% reduction of the incorporation of the radiolabel from [14C]xanthine into ATP and greater than 80% reduction of the incorporation of the label into GTP. The HPPR -MP and Form B-MP present in these cells may have inhibited the leishmanial succino -AMP synthetase and GMP reductase. The analogs had little or no effect on the pool sizes of ATP and GTP of either mouse L cells or L. donovani.

Adenylosuccinate Synthase↗
PubMed1984

Progress curve analysis of adenosine deaminase-catalyzed reactions.

The kinetic constants of the adenosine deaminase-catalyzed conversion of adenosine to inosine were found to be readily obtainable by analyzing the progress curve of a single reaction. A novel inhibitor, 9-(1-hydroxymethyl-3-methylbutyl)adenine, was studied to test the validity of the progress curve method with this enzyme. Estimates of kinetic constants determined by this method were compared to those determined by the conventional initial velocity analysis. The Km and Vmax values for adenosine and the Ki value for the inhibitor were estimated to be 26.1 microM, 1.27 mumol/min/unit of enzyme, and 0.48 microM, respectively, by the initial velocity method, and 29.3 microM, 1.27 mumol/min/unit of enzyme, and 0.52 microM, respectively, by the progress curve analysis. The inhibitor was shown to act competitively with substrate by both methods of analysis. The progress curve experiments were very simple to perform and the constants were calculated (with an interfaced microcomputer) within a few minutes of the completion of each assay.

Adenosine↗
PubMed1984

Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.

The ribonucleotide reductase (ribonucleoside-diphosphate reductase; EC 1.17.4.1) induced by herpes simplex virus type 2 infection of serum-starved BHK-21 cells was purified to provide a preparation practically free of both eucaryotic ribonucleotide reductase and contaminating enzymes that could significantly deplete the substrates. Certain key properties of the herpes simplex virus type 2 ribonucleotide reductase were examined to define the extent to which it resembled the herpes simplex virus type 1 ribonucleotide reductase. The herpes simplex virus type 2 ribonucleotide reductase was inhibited by ATP and MgCl2 but only weakly inhibited by the ATP X Mg complex. Deoxynucleoside triphosphates were at best only weak inhibitors of this enzyme. ADP was a competitive inhibitor (K'i, 11 microM) of CDP reduction (K'm, 0.5 microM), and CDP was a competitive inhibitor (K'i, 0.4 microM) of ADP reduction (K'm, 8 microM). These key properties closely resemble those observed for similarly purified herpes simplex virus type 1 ribonucleotide reductase and serve to distinguish these virally induced enzymes from other ribonucleotide reductases.

Adenosine Triphosphate↗
PubMed1983

A simple method to purify ribonucleotide reductase.

Assays of ribonucleotide reductase in extracts of Detroit 98 (human) cells were found to be complicated by the rapid depletion of the substrate (CDP) by nucleoside diphosphate kinase. Assays of either 100,000g supernatants or ammonium sulfate-fractionated extracts resulted in the conversion of greater than 90% of the substrate to CTP within 2 min. It was therefore desirable to separate nucleoside diphosphate kinase from ribonucleotide reductase. Chromatography of the fractionated extract on an ATP-agarose column resulted in the delivery of nondissociated ribonucleotide reductase in the void volume and the retention of greater than 99.9% of the nucleoside diphosphate kinase. The kinase could be eluted by 2 mM ATP. The ribonucleotide reductase was recovered from this commercially available gel with an apparent yield of greater than 200%. It could be accurately assayed with only minimal extraneous depletion of substrate. Furthermore, it was stable to storage at -80 degrees C. Tris-HCl was found to inhibit the enzyme. When HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)-Na buffer was used in place of Tris-HCl, the rate of CDP reduction was increased by 2.5-fold. Since the above procedure selectively removes nucleoside diphosphate kinase from crude preparations of ribonucleotide reductase, it should have general applicability for purifying ribonucleotide reductase from other sources.

Cells, Cultured↗
PubMed1983

Conversion of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine to acyclovir as catalyzed by adenosine deaminase.

Adenosine deaminase (ADA) was partially purified from several sources using affinity chromatography. These enzymes have the capacity to catalyze the deamination of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U) to form the antiviral agent acyclovir [9-(2-hydroxyethoxymethyl)guanine]. Their relative substrate efficiencies (Vmax/Km) with A134U (standardized to adenosine = 100) were: dog ADA, 0.092; human ADA, 0.015-0.029; rat ADA, 0.025; calf ADA, 0.016; and Escherichia coli ADA, 0.0003. In addition to having the lowest efficiency with A134U, the bacterial ADA was also distinguished by its lack of binding of the mammalian ADA inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine and by its weak binding to the 9-(p-aminobenzyl)adenine-agarose affinity column. Four minor metabolites of A134U and acyclovir have been reported to be produced in the rat. These compounds are oxidized on either the C-8 position of the ring or the terminal carbon of the side chain. Neither acyclovir nor any of these metabolites produced significant inhibition of calf intestine ADA. The oxidized metabolites containing an N-6 amino group were extremely slow substrates of this enzyme.

Acyclovir↗
PubMed1983

Ribonucleotide reductase induced by herpes simplex type 1 virus. Characterization of a distinct enzyme.

The ribonucleotide reductase induced by herpes simplex virus type 1 (HSV-1) was purified in high yield from serum-starved baby hamster kidney (BHK-21) cells infected with HSV-1 (strain H-29). The enzyme preparation was essentially free of both eucaryotic ribonucleotide reductase and contaminating enzymes that could cause significant depletion of substrates. The HSV-1-induced enzyme was assayed in 0.2 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-Na at the pH optimum of 8.1 and the optimal dithiothreitol concentration of 10 mM. Nucleoside diphosphates were the substrates of this enzyme. The HSV-1-induced ribonucleotide reductase was inhibited by anions. EDTA also inhibited the enzyme and this inhibition was not reversed by the addition of FeCl2. Hydroxyurea acted as a noncompetitive inhibitor versus CDP reduction (Kii = 1.3 mM Kis = 2.4 mM). The enzyme was inhibited by either free Mg2+ or free ATP. However, it was neither inhibited nor activated by the ATP X Mg complex. Reduction of either CDP or ADP was only weakly inhibited by dATP, dTTP, dGTP, and dCTP. No activation of this enzyme by these compounds was observed. The V'm values for reduction of CDP, UDP, and ADP were similar, while the GDP V'm was 2-fold greater. The K'm values were 80, 12, 1.2, and 0.65 microM for UDP, ADP, GDP, and CDP, respectively. The K'm values for CDP, GDP, and ADP were the lowest values observed for any ribonucleotide reductase. Each ribonucleoside diphosphate substrate competitively inhibited the reduction of each other substrate. The K'is values obtained for inhibition by a given ribonucleoside diphosphate were similar to the K'm value obtained for that compound as a substrate. Kinetic analysis of the combined rate of product formation when both CDP and ADP were simultaneously present as substrates produced patterns that were consistent with reduction at a common catalytic site. The 2'-deoxynucleoside diphosphate products were also competitive inhibitors versus the substrates. The K'is values versus CDP reduction were 310, 140, 9, and 5 microM for dUDP, dADP, dGDP, and dCDP, respectively. Similar K'is values were obtained when ADP was the substrate. All of these data are most consistent with the hypothesis that the HSV-1-induced ribonucleotide reductase catalyzes the reduction of all substrates at a common site. The apparent lack of significant allosteric modulation of HSV-1-induced ribonucleotide reductase, its kinetic behavior, and its low K'm for CDP, GDP, and ADP clearly differentiate this enzyme from other ribonucleotide reductases.

Adenosine Diphosphate↗
PubMed1982

Guanosine 5'-monophosphate reductase from Leishmania donovani. A possible chemotherapeutic target.

GMP reductase was highly purified from promastigotes of Leishmania donovani by chromatography on a single DEAE-cellulose column. Bimodal substrate saturation curves resulted in a 1/v versus 1/[GMP] plot that curved downward above 40 microM GMP. The kinetic constants were, therefore, obtained with GMP below this concentration. The K'm for GMP was 21 microM at pH 6.9. The enzyme was very sensitive to activation by GTP. At 20 microM GMP, a maximum of 600% activation occurred at 100 microM GTP. Half-maximal activation occurred at 8 microM GTP. GTP at 100 microM did not affect the K'm for GMP but did increase its V'max by 7-fold. Xanthosine monophosphate (XMP) and IMP analogs served equally well as competitive inhibitors versus GMP. The inhibition by the analogs and the activation by GTP were mutually antagonistic processes. The inhibition by the IMP analogs, allopurinol nucleotide and thiopurinol nucleotide is of chemotherapeutic interest because these compounds were shown previously to be produced in Leishmania from the anti-leishmanial agents allopurinol and thiopurinol. These nucleotides were 100- and 20-fold, respectively, more potent inhibitors of GMP reductase from L. donovani than of the corresponding enzyme from human erythrocytes.

Animals↗
PubMed1982

Antileishmanial action of 4-thiopyrazolo (3.4-d) pyrimidine and its ribonucleoside. Biological effects and metabolism.

Thiopurinol [4-thiopyrazolo(3.4-dyprimidine, TPP] and its ribonucleoside (TPPR) were effective in vitro against the intracellular and extracellular forms of L. braziliensis and L. mexicana. They also inhibited the transformation of the amastigote of L. donovani to the promastigote. These thio-analogues had about the same activity as allopurinol [4-hydroxypyrazolo(3.4-d)pyrimidine, HPP] and its ribonucleoside (HPPR). the thiopyrazolopyrimidines were converted primarily to the ribonucleoside-5' -phosphate (TPPR-MP) and to an unidentified metabolite, but not to any of the adenine ribonucleoside analogues previously shown to be formed from allopurinol and its ribonucleoside. There was an antagonism between the growth-inhibitory effects of allopurinol and thiopurinol. This is consistent with the findings that the intracellular concentrations of TPP and TPPR-MP are sufficient to inhibit the conversion of allopurinol to allopurinol ribonucleotide (HPPR-MP) by the hypoxanthine-guanine phosphoribosyltransferase by 30 per cent and the amination of HPPR-MP by adenylosuccinate synthetase by 50 per cent respectively. Consequently, the incorporation of the aminated product (aminopyrazolopyrimidine) into RNA was substantially decreased. The difference in metabolism between the thio- and hydroxypyrazolopyrimidines suggests a difference in their mechanisms of action against the pathogenic leishmania.

Allopurinol↗
PubMed1982

Adenylosuccinate synthetase and adenylosuccinate lyase from Trypanosoma cruzi, Specificity studies with potential chemotherapeutic agents.

Adenylosuccinate (succino-AMP) synthetase and succino-AMP lyase isolated from epimastigotes of Trypanosoma cruzi by chromatography on phosphocellulose. The synthetase was capable of catalyzing the condensation of aspartic acid with IMP and several IMP analogs. The reaction with allopurinol ribonucleotide is of potential chemotherapeutic interest. This analog was slowly converted to its corresponding succino-AMP analog with a Km' of 140 micrometers (cf. IMP at 10 micrometers) and a Vmax' of 0.3 per cent the rate with IMP. The comparable reaction with this analog does not occur with succino-AMP synthetase from a representative mammalian source [T. Spector and R. L. Miller, Biochim. biophys. Acta 455, 509 (1976)]. The protozoal succino-AMP lyase had a broad substrate which was characteristic of this enzyme from many sources. It catalyzed the rapid and efficient cleavage of all the succino-AMP analogs that were produced by succino-AMP synthetase. Thus, these two enzymes appear to be responsible for the selective amination of allopurinol ribonucleotide in T. cruzi. The metabolically produced AMP analog may be the agent or a precursor of the agent that accounts for the anti-growth activity of allopurinol in these organisms. Similar selective amination was observed previously with these enzymes from Leishmania donovani [T. Spector, T. E. Jones and G. B. Elion, J. biol. Chem. 254, 8422 (1979)]. Thiopurinol ribonucleotide was not a substrate of succino-AMP synthetase from T. cruzi, but it was an inhibitor with a K1 = 33 micrometers. Therefore, the weakness of thiopurinol's anti-growth activity with T. cruzi is not due to its inability to inhibit this enzyme.

Adenylosuccinate Lyase↗